Skip to content
2000
Volume 22, Issue 11
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666151210123752
2016-03-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666151210123752
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test